US · Healthcare

SAB Biotherapeutics Inc (SABS)

Biotechnology

SAB Biotherapeutics Inc (SABS) is listed on US in the Healthcare sector. Industry: Biotechnology. As of 2026-05-23, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for SABS

P/E ratio

25.00

SAB Biotherapeutics Inc (SABS) — FAQ

What is SABS's P/E ratio?

The price-to-earnings (P/E) ratio for SAB Biotherapeutics Inc (SABS) is 25.00 (data as of 2026-05-23).

Does SAB Biotherapeutics Inc pay a dividend?

Dividend yield is not available in the current snapshot for SAB Biotherapeutics Inc (SABS). Check the MyAverix Finance app for the latest dividend data.

What sector is SAB Biotherapeutics Inc in?

SAB Biotherapeutics Inc (SABS) is classified in the Healthcare sector (Biotechnology industry).

What exchange is SABS listed on?

SABS is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)